/ Not yet recruitingPhase 1 一项在晚期转移性去势抵抗性前列腺癌成人患者中评估INV-9956的安全性、药代动力学特征、药效动力学特征和初步抗肿瘤活性的多中心、开放性I期临床研究
[Translation] A multicenter, open-label Phase I clinical study evaluating the safety, pharmacokinetic, pharmacodynamic and preliminary antitumor activity of INV-9956 in adult patients with advanced metastatic castration-resistant prostate cancer
确定推荐剂量范围和/或最大耐受剂量,并评估INV-9956口服给药在晚期转移性去势抵抗性前列腺癌成年患者中的剂量限制性毒性;评估INV-9956在晚期转移性去势抵抗性前列腺癌成年患者中的安全性、耐受性、PK/PD特征和初步抗肿瘤活性。
[Translation] To determine the recommended dose range and/or maximum tolerated dose and evaluate the dose-limiting toxicity of oral INV-9956 in adult patients with advanced metastatic castration-resistant prostate cancer; to evaluate the safety, tolerability, PK/PD characteristics and preliminary antitumor activity of INV-9956 in adult patients with advanced metastatic castration-resistant prostate cancer.
/ Not yet recruitingPhase 1 一项在激素受体阳性、人表皮生长因子受体2阴性的(HR+/HER2-)晚期/转移性乳腺癌或局部晚期/转移性实体瘤成人患者中评估INV-6452安全性、药代动力学和初步抗肿瘤活性的多中心、开放性首次人体I期临床研究
[Translation] A multicenter, open-label, first-in-human Phase I clinical study evaluating the safety, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced/metastatic breast cancer or locally advanced/metastatic solid tumors
确定推荐剂量范围和/或最大耐受剂量,并评估INV-6452口服给药在晚期/转移性HR+/HER2-乳腺癌或局部晚期/转移性实体瘤成年患者中的剂量限制性毒性;评估INV-6452在晚期/转移性HR+/HER2-乳腺癌或局部晚期/转移性实体瘤成年患者中的安全性、耐受性、PK/PD特征和初步抗肿瘤活性。
[Translation] To determine the recommended dose range and/or maximum tolerated dose and evaluate the dose-limiting toxicities of oral INV-6452 in adult patients with advanced/metastatic HR+/HER2- breast cancer or locally advanced/metastatic solid tumors; to evaluate the safety, tolerability, PK/PD characteristics and preliminary antitumor activity of INV-6452 in adult patients with advanced/metastatic HR+/HER2- breast cancer or locally advanced/metastatic solid tumors.
100 Clinical Results associated with Guangdong Innovative Drug Translational Medicine Research Institute Co., Ltd.
0 Patents (Medical) associated with Guangdong Innovative Drug Translational Medicine Research Institute Co., Ltd.
100 Deals associated with Guangdong Innovative Drug Translational Medicine Research Institute Co., Ltd.
100 Translational Medicine associated with Guangdong Innovative Drug Translational Medicine Research Institute Co., Ltd.